Oscar Health, Inc. is a healthcare technology firm providing health plans to individuals, families, and employer groups in the United States, distinguishing itself with an integrated approach that includes the +Oscar platform for healthcare entities. Operating within the Healthcare Plans industry, the company aims to enhance engagement and recommendations for providers and payers through its technology-driven solutions. In its most recent reported quarters, Oscar Health experienced a mixed performance. For Q3 2025, the company reported an actual EPS of -0.53, beating the estimated -0.58019, and revenue was 2.99 billion. This followed Q2 2025 where actual EPS was -0.89 against an estimate of -0.836, with revenue at 2.86 billion. Comparing these to the prior two quarters, Q1 2025 saw actual EPS of 0.92 against an estimate of 0.8075 and revenue of 3.05 billion, while Q4 2024 had an actual EPS of -0.62 against an estimate of -0.58224 and revenue of 2.39 billion. The trend shows a deceleration in EPS performance from Q1 2025 to Q2 2025, with revenue showing growth from Q4 2024 to Q1 2025, followed by a slight dip in Q2 2025. Historically, Oscar Health has demonstrated a pattern of revenue growth, though EPS performance has been more volatile, with several quarters missing analyst estimates. For instance, Q4 2024 and Q2 2025 saw EPS misses, while Q3 2025 was a beat. The company has shown an ability to grow revenue year-over-year, but the profitability metrics have been inconsistent, indicating a focus on top-line expansion. Recent news highlights Oscar Health's strong push towards profitability in 2026, driven by AI efficiencies and strategic rate increases, alongside a reaffirmed outlook and a robust reinsurance strategy. The company is also preparing for its Q1 2026 earnings release, with investors closely watching commentary on finalized CMS Medicare Advantage payment policies for 2027, which could be favorable for revenue streams. Analyst optimism, including an upgrade to Outperform by Raymond James, suggests a potentially appealing valuation and anticipated margin recovery. Looking ahead, investors will be watching for continued execution towards positive earnings in 2026, as this remains a critical focus. Key will be how the company navigates the impact of finalized CMS payment policies on its outlook and whether its AI-powered efficiencies and strategic rate increases translate into sustained profitability and improved operating margins.
